CSL Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 4/6

CSL kazançlarla iyi bir şekilde karşılanan, 1.43% cari getiriye sahip, temettü ödeyen bir şirkettir.

Anahtar bilgiler

1.4%

Temettü verimi

-0.05%

Geri Alım Getirisi

Toplam Hissedar Getirisi	1.4%
Gelecekteki Temettü Verimi	2.1%
Temettü Büyümesi	-4.0%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	€3.992
Ödeme oranı	48%

Son temettü ve geri alım güncellemeleri

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CSJ şirketinin hisse başına düşen temettüsü son 10 yıldır istikrarlıydı.

Büyüyen Temettü: CSJ şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.

Piyasaya Karşı Temettü Getirisi

CSL Piyasaya Karşı Temettü Getirisi

CSJ temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CSJ)	1.4%
Pazarın Alt %25'i (DE)	1.7%
Pazarın En İyi %25'i (DE)	4.8%
Sektör Ortalaması (Biotechs)	1.6%
Analist tahmini (CSJ) (3 yıla kadar)	2.1%

Önemli Temettü: CSJ şirketinin temettüsü ( 1.43% ), German pazarındaki temettü ödeyenlerin en alttaki %25'ine ( 1.73% ) kıyasla dikkate değer değil.

Yüksek Temettü: CSJ 'in temettüsü ( 1.43% ), German piyasasındaki temettü ödeyenlerin en üst %25'ine ( 4.81% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Oldukça düşük ödeme oranı ( 48.3% ) ile CSJ 'un temettü ödemeleri kazançlarla oldukça iyi bir şekilde karşılanıyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Mevcut nakit ödeme oranı ( 84.9% ) ile CSJ 'un temettü ödemeleri nakit akışları tarafından karşılanmaktadır.

CSL Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 4/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Upcoming dividend of US$1.45 per share

Upcoming dividend of US$1.19 per share

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

Upcoming dividend of US$1.29 per share at 1.4% yield

Upcoming dividend of US$1.07 per share at 1.1% yield

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Recent updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

Now 20% undervalued

Upcoming dividend of US$1.45 per share

Final dividend of US$1.45 announced

Full year 2024 earnings released: EPS: US$5.47 (vs US$4.55 in FY 2023)

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Now 20% undervalued

Now 22% undervalued

Now 20% undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Now 22% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold €3.3m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings released: EPS: US$4.55 (vs US$4.81 in FY 2022)

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of US$1.07 per share at 1.1% yield

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

Now 21% undervalued after recent price drop

Independent Non-Executive Director recently bought €174k worth of stock

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Non-Independent Non-Executive Director recently sold €4.3m worth of stock

Upcoming dividend of US$1.18 per share

Full year 2022 earnings released: EPS: US$4.81 (vs US$5.22 in FY 2021)

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Now 23% undervalued

Upcoming dividend of US$1.04 per share

Now 22% undervalued after recent price drop

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

Vifor Says Regularly in Talks with Other Market Participants After Reports

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

MD, CEO & Executive Director recently sold €2.9m worth of stock

MD, CEO & Executive Director recently sold €3.0m worth of stock

High number of new directors

Upcoming dividend of US$1.18 per share

Full year 2021 earnings released: EPS US$5.22 (vs US$4.63 in FY 2020)

CSL Limited Provides Financial Guidance for Fiscal 2022